RenovoRx, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $43,000 | — | — | — |
| Gross profit | $796,000 | $43,000 | — | — | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Operating expenses | $13.3M | $11.0M | $11.4M | $9.9M | $5.7M |
| Cost of revenue | $327,000 | $0 | — | — | — |
| Cash from operations | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Capital expenditure | $2,000 | $12,000 | — | — | — |
| Free cash flow | -$11.0M | -$9.1M | — | — | — |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938,000 |
Shares outstanding 45.1M · Free float 86.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.